CTLA-4 drugs for Non-Small Cell Lung Cancer

4 tracked CTLA-4 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the CTLA-4 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.

1 approved / phase 41 Phase 31 Phase 21 Phase 1/2

Head-to-head evidence: Botensilimab vs Tremelimumab · Evalstotug vs Tremelimumab · Gotistobart vs Tremelimumab

The roster

← all CTLA-4 drugs